Aptevo Therapeutics
APVO | NASDAQ
$0.55
-$0.04 (-7.42%)
At close: Nov 16, 2026, 4:00 PM ET
$0.55
$0.00 (-0.47%)
After-hours:
Nov 16, 2026, 5:14 PM ET
-7.42%
(1D)No price chart data available for 1D timeframe.
Rating
28
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #855/1021 (Top 84%)
Key Statistics
Market Data
Market Cap $1.2M
1D Range
0.55 0.61
52W Range
0.55 25.02
Valuation (TTM)
PE 0
PB 0.20
EV/EBITDA 0.17
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -2112.4%
SBC Adj. FCF Yield -2128.6%
SBC Impact -0.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
-100.0%
Dil EPS 3Y | 5Y 147.6% |
7.4%
FCF 3Y | 5Y -2.1% |
-13.0%
Returns
ROA -181.9%
ROE -201.5%
ROIC -262.3%
Financial Health
Net Cash
$9.8M
Current Ratio 2.08
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost in...
Sector Healthcare
Industry Biotechnology
Employees 33
IPO Date Jul 20, 2016
Website www.aptevotherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove APVO